Literature DB >> 25903212

A new diagnosis of acute myeloid leukaemia complicated by peripancreatic tuberculous lymphadenitis.

Patrick Harrington1, Tullie Yeghen2.   

Abstract

A 29-year-old woman presented with neutropenic sepsis and was found to have a new diagnosis of acute myeloid leukaemia. Following initiation of induction chemotherapy the patient became increasingly unwell with ongoing sepsis despite broad-spectrum antibiotic treatment. An extensive septic screen failed to identify a source, other than the finding of a peripancreatic mass on imaging. Following the introduction of antituberculous treatment the patient showed signs of clinical improvement and a subsequent biopsy confirmed the mass to be tuberculous lymphadenitis. The patient completed three cycles of combination chemotherapy achieving a complete remission and also successfully completed 12 months of antituberculous treatment. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25903212      PMCID: PMC4420803          DOI: 10.1136/bcr-2015-209847

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  [Clinical analysis of 44 cases of leukemia complicated with active tuberculosis-a single-center report].

Authors:  Jun Li; Meng Jiang; Yi-ming Yang; Ting Liu; Ting Niu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2013-07

Review 2.  BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.

Authors: 
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

3.  Acute myeloid leukaemia complicated by anergic tuberculosis.

Authors:  K Patel; P R Kelsey
Journal:  Clin Lab Haematol       Date:  1996-03

4.  Tuberculosis in acute leukemia: a clinico-hematological profile.

Authors:  Pravas Mishra; Rajat Kumar; Manoranjan Mahapatra; Sanjay Sharma; Ashish Dixit; Tathagat Chaterjee; D R Choudhry; Renu Saxena; V P Choudhry
Journal:  Hematology       Date:  2006-10       Impact factor: 2.269

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.